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Tumor associated gene-1/L amino acid transporter-1
(TA1/LAT-1) was recently identified as a light chain of
the CD98 amino acid transporter and cellular activation
marker. Our previous studies with primary rat hepato-
cyte cultures demonstrated that TA1 RNA levels were
responsive to media amino acid concentrations, suggest-
ing adaptive regulation. High level TA1 expression asso-
ciated with transformed cells also suggested a role in
tumor progression. The present study examined the re-
lationship of TA1/CD98 expression, adaptive response,
and associated amino acid transport to neoplastic trans-
formation using a panel of well characterized rat he-
patic cell lines. We found 1) increased expression of TA1
in response to amino acid depletion, specific for argi-
nine but not glutamine; 2) loss of TA1 response to argi-
nine in g-glutamyl transpeptidase-positive transformed
and tumorigenic cells; 3) no appreciable response of 4F2/
CD98 heavy chain to arginine levels; and 4) correlation
of system L amino acid transport activity in response to
arginine with changes in TA1/LAT-1 mRNA but not total
immunoreacting protein. Our results suggest this CD98
light chain may act as an environmental sensor, re-
sponding to amino acid availability and that its regu-
lation is complex. We hypothesize that altered TA1 ex-
pression is an early event in hepatocarcinogenesis
giving neoplastic cells a growth or survival advantage,
particularly under conditions of limited amino acid
availability.
TA11 was cloned in our laboratory on the basis of its differ-
ential expression between rat hepatoma cells and normal adult
rat liver and encodes a predicted integral membrane protein
with several membrane-spanning domains (1). TA1 is identical
to the C terminus (amino acids 272–512) of LAT-1, which is a
512-amino acid protein with 12 transmembrane domains (2).
E16, cloned as a lymphocyte activation antigen, is the human
homolog of TA1 and is 95% identical at the amino acid level (3).
TA1/LAT-1 is a member of an emerging family of highly con-
served molecules with homologs in Xenopus, Schistosoma,
mouse, and man. More recently, TA1/LAT-1 and its homologs
have been identified as the light chain of the CD98 molecule (2,
4–8). The CD98 complex consists of an 80-kDa heavy chain
(4F2) and a 40–45-kDa light chain (9). CD98 has been impli-
cated in a variety of functions including amino acid transport,
cell survival, integrin activation, and cell fusion (10–13). Ad-
ditional light chains have been identified and designated
y1LAT-1 (14–16), y1LAT-2 (14, 17), and LAT-2 (18, 19). The
CD98 complex can mediate System L or System y1L amino acid
transport in Xenopus oocytes depending on which CD98 light
chain (CD98lc) is associated with the CD98 heavy chain
(CD98hc) (2, 6–8, 14). Co-injection of cRNA for TA1/LAT-1 and
4F2 has been shown to mediate System L transport of large
neutral amino acids with branched or aromatic side chains in
Xenopus oocytes (2, 6). LAT-2 also mediates System L transport
in Xenopus oocytes upon co-injection with 4F2hc; however,
LAT-2 transports both large and small neutral amino acids
with a lower affinity (Km) than LAT-1 (18, 19). TA1/LAT-1 is
not only expressed in rat hepatomas but also in a variety of
human cancers including human colon and breast carcinoma
(20). Whereas TA1 expression is not seen in normal adult rat
liver, it can be induced transiently in liver and with the same
kinetics as c-myc after acute carbon tetrachloride injury, sug-
gesting a role in normal injury response in this organ (21). In
primary hepatocyte cultures, we also observed that changes in
amino acid concentrations resulted in altered levels of TA1
expression, suggesting adaptive regulation (22).
We are interested in examining the regulation and role of
TA1/E16 and CD98-related molecules in hepatocarcinogenesis.
We have utilized a panel of rat hepatic WB cell lines that differ
in their transformed and tumorigenic properties. We have as-
sessed how basal TA1/CD98lc and 4F2/CD98hc expression in
response to an environmental factor, arginine availability, are
associated with transformation and tumorigenicity in this sys-
tem. We have found regulation at the level of TA1/CD98lc. The
possible physiological significance of this regulation is dis-
cussed. 4F2/CD98hc RNA levels remained fairly constant re-
gardless of arginine availability, transformation, or tumorige-
nicity. TA1/CD98lc RNA levels, but not the total pool of
immunologically reactive protein, were found to be modulated
by arginine availability in nontransformed and GGT-negative
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transformed WB cells. TA1/CD98lc RNA levels were constitu-
tively high in GGT-positive transformed cells and hepatomas,
and TA1/CD98lc protein levels were elevated relative to non-
transformed cells. System L amino acid transport was signifi-
cantly higher in GGT-positive transformed, tumorigenic cells
than nontransformed cells and responded to availability of
arginine, a nonsystem L substrate.
EXPERIMENTAL PROCEDURES
Cell Culture—A brief description of all cell lines used in this study
including data on transformation and tumorigenicity is presented in
Table I. The normal diploid hepatic epithelial line WB-F344 (WB) was
isolated from an adult male Fischer 344 rat (23). The derivative cell
lines were produced by 11 brief repeated exposures of WB-F344 cells to
5 mg/ml of N-methyl-N9-nitro-N-nitrosoguanidine, and from this heter-
ogeneous, tumorigenic cell population, 18 clonal subpopulations were
isolated based on their expression of the oncofetal marker enzyme GGT
(24). Cloned cell lines were determined to be either GGT-negative (i.e.
GN6) or GGT-positive (i.e. GP6). Cell lines were also re-established
from subcutaneous tumors derived from GGT-positive (i.e. GP6TB,
GP7TB) and GGT-negative cells (i.e. GN6TF). 1683 cells are rat trans-
plantable hepatocellular carcinoma cells derived from primary carcino-
mas induced by a choline-deficient, ethionine diet (25).
WB, GN6, GN6TF, and GP7TB cell lines were routinely cultured in
Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.) containing
10% FBS, whereas GP6 and GP6TB were routinely cultured in Dulbec-
co’s modified Eagle’s medium /Ham’s F-12 (1:1) (Life Technologies, Inc.)
containing 10% FBS and supplemented with insulin, transferrin, sel-
enous acid, bovine serum albumin, and linoleic acid at 1 ml/100 ml
medium (Becton Dickinson). 1683 cells were routinely cultured in Way-
mouth’s medium containing 10% FBS. To better simulate the normal
hepatic milieu, a custom formulation of Chee’s essential medium (CEM)
demonstrated to maintain long term differentiated hepatic cell function
in vitro was kindly provided by Dr. Hugo Jauregui (Department of
Pathology, Rhode Island Hospital) and prepared as described previ-
ously (26). Arginine and glutamine were not present in this custom
formulation and were added from stock solutions. It was not feasable to
selectively delete other amino acids with this medium because custom
batches missing other amino acids were only available in 100-liter
batches. For experiments in which gene expression was assayed as a
function of arginine availability, cells were seeded into T-75 flasks with
CEM containing 5% FBS dialyzed or undialyzed with arginine or with-
out arginine. All experiments with all the cell lines were repeated with
dialyzed serum to remove serum as a source of arginine with similar
results to nondialyzed serum. Medium was changed every day. Viability
was at least 90% in all cases.
RNA Preparation and Northern Blot Analysis—Total RNA was iso-
lated using the guanidinium isothiocyanate/cesium chloride method
(27) for normal adult rat liver and a modification of that method for
cultured cell lines (Totally RNA Kity; Ambion, Austin, TX). RNA was
isolated from cultured cells after subculture in CEM at the appropriate
TABLE I
Characteristics of cell lines used in this study
Description of cell lines used in this study as: 1) either positive or negative for transformation (defined as treatment with carcinogen and ability
to form a tumor in a subcutaneous site); 2) GGT expression; 3) derivation from an in vivo tumor source; 4) high, low, or negative for tumorigenicity
at a subcutaneous site or in the liver; and 5) positive or negative for derivation from WB parental rat cell line.
Characteristic WB GN6 GN6TF GP6 GP6TB GP7TB 1683
Transformed 2 1 1 1 1 1 1
GGT 2 2 2 1 1 1 ?
In vivo source 2 2 1 2 1 1 1
Tumorigenicity (subQ) 2 1 1 1 1 1 11
Tumorigenicity (liver) 2 2 2 2 1 1 11
WB-derived 1 1 1 1 1 1 2
FIG. 1. CD98lc/TA1 and CD98hc/4F2 response to amino acid
availability in WB cells. Shown is total RNA from WB cells cultured
in CEM without arginine (2R), without arginine and glutamine (2R/
2Q), without glutamine (2Q), or CEM with arginine and glutamine
(1R/1Q) for 48, 72, and 96 h. Aliquots (12 mg) of total RNA were
analyzed by sequential Northern blot hybridization to a 900-bp TA1
probe (top panel), a 1.8-kbp 4F2 probe (middle panel), and a 1.25-kbp
GAPDH probe (bottom panel). RNA from 1683 rat hepatoma cells and
normal adult rat liver were included for comparison. Ethidium bromide
staining was used as a loading control between lanes. Approximate
transcript size is indicated to the right. Arginine, but not glutamine,
availability modulated TA1 RNA levels, whereas neither arginine nor
glutamine availability changed 4F2 RNA levels.
FIG. 2. Time course of CD98lc/TA1 and CD98hc/4F2 response to
arginine availability in WB cells. Shown is total RNA from WB cells
cultured with arginine (1R) or without arginine (2R) for 4, 8, 24, and
48 h. Aliquots (12 mg) of total RNA were analyzed by sequential North-
ern blot hybridization to a 900-bp TA1 probe (top panel), a 1.8-kbp 4F2
probe (middle panel), and a 1.25-kbp GAPDH probe (bottom panel).
Ethidium bromide staining was used as a loading control between
lanes. Approximate transcript size is indicated to the right. Steady state
TA1 mRNA levels increased within four hours of culture without argi-
nine versus with arginine. Although TA1 mRNA was induced up to
ten-fold in WB cells cultured without arginine, 4F2 mRNA levels were
induced only 2–3-fold in cells cultured without arginine after densito-
metric analysis with normalization to GAPDH mRNA levels.
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time points. Aliquots (12 mg) of total RNA were size fractionated on 1%
agarose/formaldehyde gels as described previously (20). After electro-
phoresis, gels were equilibrated in 1 M ammonium acetate, and RNA
was transferred to Nytran nylon membranes (Schleicher & Schuell).
Blots were baked for 2 h at 80 °C and hybridized at 65 °C according to
Church and Gilbert (28). Rat TA1 p900, a fragment corresponding to
nucleotides 816–1536 of the full-length rat LAT-1, inserted into Blue-
script SK vector was labeled with [32P]dCTP (NEN Life Science Prod-
ucts; 3000 Ci/mmol) by random primed labeling (Roche Molecular Bio-
chemicals) for use as a probe. Blots wrapped in plastic wrap were
exposed to x-ray film (Eastman Kodak Co.) at 270 °C in the presence of
intensifying screens. Blots were stripped and rehybridized to an
1800-bp EcoRI fragment of human 4F2hc (provided by Dr. Martin
Hemler) (29). Blots were also stripped and hybridized to an 800-bp
fragment of the 59 end of LAT-1 derived through reverse transcription-
polymerase chain reaction of the 1600-bp coding region of LAT-1 using
rat placenta as an RNA source followed by polymerase chain reaction of
the 59 end of LAT-1. A 1.25-kbp PstI fragment of human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used in combination with
ethidium bromide staining to evaluate RNA loading variations (30).
Densitometry using the Quantity Oney IBM software package was
used to quantify differences in RNA levels with normalization to 18 S
ribosomal RNA.
Amino Acid Transport Assays—The transport of radiolabeled amino
acids by cell monolayers was performed using a modification of the
cluster tray method developed by Gazzola et al. (31), and described by
Kilberg (32). All 3H-labeled amino acids were purchased from NEN Life
Science Products, and unlabeled amino acids were purchased from
Sigma. Cells were seeded in 24-well trays such that the cells would be
near confluent for the transport assay. Before the transport assays,
cells were rinsed with warm Na1-free Krebs-Ringer phosphate buffer
(cholKRP), in which the sodium containing salts were iso-osmotically
replaced with choline, to remove extracellular Na1 and amino acids.
Cells were incubated in warm cholKRP for 10 min to deplete intracel-
lular amino acids. The uptake of radiolabeled amino acids (5 mCi of
3H-amino acid/ml) at 100 mmol/liter in either 200 ml of cholKRP or
NaKRP was measured for 30 s at 37 °C. Preliminary experiments
indicated that uptake of each 3H-labeled amino acid was linearly de-
pendent on incubation time up to at least 3 min; therefore, uptake was
measured for 30 s (data not shown). In inhibition experiments, excess
cold amino acid was added to the uptake buffer at 10 mM final concen-
tration. Uptake was terminated by washing the cells rapidly four times
with 1 ml/well of ice-cold cholKRP. After the trays were allowed to dry,
the cells were incubated for 1 h with 0.2 ml/well of 0.2% (w/v) SDS plus
0.2 N NaOH to release intracellular radioactivity. A 0.1-ml aliquot from
each well was neutralized with 0.1 ml of 0.2 N HCl and quantified in a
Beckman LS 6000SC liquid scintillation counter. The remaining 0.1 ml
was analyzed for protein content using the BCA protein assay reagent
(Pierce). Transport velocities were calculated from radioactive counts,
specific activities of uptake mixes, and protein absorbance values and
expressed as pmol amino acid transported per milligram of protein per
minute (averages 6 S.E. of at least three separate determinations).
Data comparing two experimental results were analyzed statistically by
Student’s t test using the InStat Macintosh statistics program. Each
experiment was repeated at least twice to show qualitatively the same
results.
Immunoblot Analysis—Detergent extracts were prepared from WB,
GP6, and GP7TB cells cultured under the same conditions as for RNA
preparation and analyzed by SDS-polyacrylamide gel electrophoresis as
described previously (20). Rabbit antibodies prepared to synthetic pep-
tides corresponding to amino acids 211–221 of TA1/E16 (482–492 of
LAT-1) deduced sequence were used together with chemiluminescence
detection as described previously (20). Two rabbits (K and G) were
immunized with the identical preparation of keyhole limpet hemocya-
min-conjugated peptide. A recombinant fusion protein of TA1 with six
histidines produced in baculovirus and purified by nickel affinity chro-
matography as previously reported (4) served as positive control. As a
negative control, blots were reacted with nonimmune rabbit serum at
the same dilution.
RESULTS
TA1 mRNA Is Induced Following Arginine Deprivation of
WB Cells While 4F2hc mRNA Levels Remain Invariant—In
previous studies with primary hepatocyte cultures, we found
that TA1 mRNA levels could be either induced or suppressed
depending on the culture medium and its amino acid concen-
trations (22). We extended these studies to examine whether
the same response to amino acid availability was found in a
normal rat liver epithelial cell line, WB, and whether depriva-
tion of arginine and/or glutamine, the two amino acids manip-
ulable in our culture system, could increase TA1 expression in
these cells. WB is a diploid cell line isolated from the liver of an
adult male Fischer-344 rat and has been used extensively as
both an in vitro and an in vivo model system for the liver (23,
33). WB cells were cultured in CEM, CEM without arginine,
CEM without glutamine, or CEM without arginine or gluta-
mine for 48, 72, and 96 h. Using densitometry and normalizing
to GAPDH, steady state levels of TA1 RNA were 8–10-fold
higher in WB cells cultured in the absence of arginine than in
the presence of arginine (Fig. 1). Thus, the availability of argi-
nine was found to modulate TA1 expression, whereas gluta-
mine availability had no effect. The apparent increase in TA1
observed after WB cells are cultured for 48 h without glutamine
was found to be negligible after standardization to ethidium
staining and GAPDH hybridization. In stark contrast to TA1,
4F2 mRNA levels did not vary in response to arginine avail-
ability. Similarly, glutamine availability did not affect 4F2
expression. Other amino acids were not examined because of
constraints of medium composition. Since arginine availability
was found to modulate TA1 mRNA levels in these nontrans-
formed nontumorigenic cells, we used arginine availability sub-
sequently as a tool to examine the regulation of TA1 and 4F2 in
a panel of rat hepatic cell lines differing in stages of transfor-
mation and tumorigenicity.
Early Response of TA1 and 4F2 mRNA to Arginine Availabil-
ity—To determine the time course of the observed response, we
examined TA1 and 4F2 steady state message levels at addi-
tional time points in WB cells cultured with and without argi-
nine. WB cells were cultured in Dulbecco’s modified Eagle’s
medium, trypsinized and then seeded and cultured in CEM
with or without arginine for 4, 8, 24, and 48 h. The results are
presented in Fig. 2. TA1 steady state mRNA levels were re-
sponsive to arginine availability in WB cells within four hours
FIG. 3. Expression of CD98lc/TA1 and CD98hc/4F2 in cultured
GN6 and GN6TF cells in response to arginine availability. Shown
is total RNA from GN6 and GN6TF cells cultured in CEM with or
without arginine for 24, 48, and 72 h. Aliquots (12 mg) of total RNA were
analyzed by Northern blot hybridization to a 900-bp TA1 probe (top
panel), stripped and then rehybridized with a 1.8-kbp 4F2hc probe
(middle panel), or stripped and then rehybridized with a 1.25-kbp
GAPDH probe (bottom panel). Ethidium bromide staining was used as
a loading control between lanes. Approximate transcript sizes are indi-
cated to the right. Steady state TA1 RNA levels were high in cells
cultured without arginine but were gradually lowered in cells cultured
with arginine. 4F2 RNA levels were constitutively high.
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after culture in CEM without arginine. After densitometric
normalization to GAPDH steady state mRNA levels, TA1
mRNA levels were approximately ten-fold greater in cells cul-
tured without arginine for four hours versus with arginine.
Normalized 4F2 mRNA levels at this time point were approx-
imately 2.5 fold higher in WB cells cultured without arginine
versus with arginine. For subsequent experiments, we chose to
examine differences between response of normal and trans-
formed, tumorigenic cell lines at time points from 24 to 72 h,
since cell attachment and spreading of this integrin-associated
molecule may confound data interpretation.
TA1 and 4F2 RNA Levels Differentially Respond to Arginine
Availability in GGT-negative Transformed WB Cells versus
GGT-positive Transformed WB Cells—Loss of response to pos-
itive/negative signals is one of the major events marking the
transition from a normal to a malignant cell. We examined TA1
and 4F2 response to arginine availability in chemically trans-
formed GGT-negative (GN6) and GGT-positive (GP6) WB cells,
and tumor derived WB cell lines which were both GGT-nega-
tive (GN6TF) and GGT-positive (GP6TB, GP7TB) to determine
if TA1 and/or 4F2 response would correlate with transforma-
tion, GGT status, or tumorigenicity. Normally, GGT is ex-
pressed in fetal rat hepatocytes, adult bile duct cells, and
kidney, but during hepatocarcinogenesis it becomes up-regu-
lated as an early event in neoplastic conversion. Hanigan has
elegantly demonstrated that GGT-negative and GGT-positive
mouse hepatoma (Hepa 1–6) cells grow similarly in cysteine-
rich medium (.100 mM cysteine), but at physiological concen-
trations of cysteine (,100 mM cysteine), GGT expression con-
fers a selective growth advantage on GGT-positive mouse
hepatoma cells (34). Cells were cultured in CEM with or with-
out arginine for 24, 48, and 72 h prior to RNA extraction.
Northern analysis was performed and the results are shown in
Figs. 3 and 4. Although 4F2 expression remained fairly con-
stant in all cells, conditions, and time points, TA1 expression
varied considerably. In the GGT-negative WB lines, TA1 RNA
levels increased 8 to 10 fold in the absence of arginine for 72 h.
In contrast, expression increased only about 2 to 4 fold in
GGT-positive transformed cells largely because of higher basal
level expression in the presence of arginine. Similar results
were also obtained at the earlier time points, although the fold
differences were lower.
Despite the transformation status of these cell lines, in all
cases TA1 RNA was expressed at a high level in cells cultured
without arginine. Interestingly, although basal 4F2 expression
was about 2-fold greater in transformed cells, it remained fairly
constant for each cell type whether or not arginine was present
in the medium. At early time points after culture in CEM,
GGT-negative transformed cells express high levels of TA1
regardless of arginine availability, similar to GGT-positive
cells at all time points. After 72 h of culture in the presence of
arginine, reduced TA1 levels were observed in GGT-negative
transformed cells similar to those seen in nontransformed WB
cells cultured in CEM with arginine. These results imply the
loss of regulation of TA1 at different stages of progression in
these rat hepatic lines.
TA1 and 4F2 Are Constitutively Expressed in a Non-WB Rat
Hepatoma Cell Line—We also examined the response of TA1
and 4F2 in another rat hepatoma cell line separate from the
WB tumor-derived cell lines. In contrast to WB lines that were
transformed by carcinogen treatment in vitro, 1683 cells are rat
transplantable hepatocellular carcinoma cells derived from pri-
mary carcinomas induced by feeding rats a choline-deficient,
ethionine diet (25). 1683 cells were cultured in CEM with or
without arginine for 24, 48, and 72 h. Neither TA1 nor 4F2
expression significantly changed whether or not arginine was
included in the medium (Fig. 5). Steady state levels of both
messages were high all the time, with only slight increases of
TA1 expression (2–3-fold) at 72 h after arginine deprivation.
These cells constitutively express high levels of TA1/CD98lc
and 4F2/CD98hc message. Thus loss of arginine response does
not appear related to the type of carcinogen involved in
transformation.
Relative TA1 and 4F2 mRNA Levels in All Cell Lines Exam-
ined—RNA samples from each cell line were included on the
same Northern blot so that comparisons could be made be-
tween all the cell lines. These results are presented in a graph
in Fig. 6. Each bar represents the average densitometric value
determined from three independent blots. 4F2/CD98hc RNA
levels are fairly constant in every cell line, and every time point
examined had no greater than a 2-fold difference between cells
cultured with or without arginine. WB cells have the lowest
TA1 and 4F2 RNA levels in all conditions and time points,
although TA1 RNA levels do increase 8–10-fold when cells are
FIG. 4. Expression of CD98lc/TA1
and CD98hc/4F2 in cultured GP6,
GP6TB, and GP7TB cells in response
to arginine availability. Shown is total
RNA from GP6, GP6TB, and GP7TB cells
cultured in CEM with or without arginine
for 24, 48, and 72 h (Note: RNA for GP6
cells at 24 h was not available). Northern
blot hybridization of total RNA (12 mg)
was analyzed by sequential hybridization
to probes for TA1 (top panel), 4F2hc (mid-
dle panel), and GAPDH (bottom panel).
Ethidium bromide staining was used as a
loading control between lanes. Approxi-
mate transcript sizes are indicated to the
right. Neither TA1 nor 4F2 RNA levels
varied significantly in any cell line (more
than 2–3-fold) under these culture
conditions.
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cultured without arginine. When GN6 and GN6TF cells were
cultured in medium with arginine, TA1 RNA levels showed a
large decrease from 24 to 72 h relative to cells maintained
without arginine. It is also interesting to compare the TA1
response to arginine availability by in vitro transformed cells
(GP6 cells) versus cell cultures derived from solid tumors of
these cells (GP6TB). In both GP6 and GP6TB, TA1 RNA levels
differ only about 2–4-fold during the course of culture with or
without arginine. GP6TB cells, however, express higher basal
levels of both TA1 and 4F2 than GP6 cells and also induce
higher levels of TA1 when cells are cultured without arginine,
suggesting an alteration associated with tumor progression.
System L Transport Is Differentially Regulated in Nontrans-
formed Versus GGT-positive Transformed and Tumorigenic
Rat Hepatic Cells—Because TA1/LAT-1 functions as the light
chain of CD98 and has been demonstrated to mediate system L
transport in Xenopus oocytes, we hypothesized that the altered
expression of TA1 was likely to be associated with differences
in transport activity. We thus examined whether arginine
availability affected system L amino acid transport in WB cells
and whether there were differences between nontransformed
and transformed GGT-positive tumorigenic lines. As shown in
Fig. 7a, WB cells cultured without arginine for 48 h trans-
ported approximately 3-fold more leucine (significant at p ,
0.05) than WB cells cultured in the presence of arginine regard-
less of the presence of sodium. As expected, addition of excess
cold tyrosine inhibited leucine transport, consistent with sys-
tem L activity. Arginine transport (system y1) was not signif-
icantly different in WB cells cultured with or without arginine
(Fig. 7b). As shown in Fig. 7c, GP7TB cells cultured without
arginine for 48 h also transported significantly more leucine
(about 2.5-fold) than GP7TB cells cultured with arginine. Ar-
ginine transport was not significantly different in GP7TB cells
under the two culture conditions (Fig. 7d).
GP7TB cells transported approximately 50% more leucine
than WB cells whether the cells were cultured with arginine or
without arginine (significant at p , 0.05). These data correlate
well with TA1 mRNA levels in GP7TB and WB cells cultured
with and without arginine for 48 h (compare Figs. 1 and 4) and
are consistent with its role as a system L transporter. The
increase in transport seen in these cells is less than the in-
crease in mRNA levels, suggesting that transcriptional mech-
anisms alone are unlikely to account for regulation.
TA1 Immunoreactive Protein Pools Are Elevated in Trans-
formed and Tumorigenic Cell Lines—To determine whether
levels of TA1 protein in transformed lines derived from the WB
line were increased relative to normal hepatic cells and how
these levels compared with transport activity, immunoblot
analysis was performed with anti-TA1 peptide antibodies
(Fig. 8). Lanes were loaded with equivalent amounts of total
protein per cell extract (15 mg), as confirmed by Ponceau S
staining after gel transfer (not shown). Relative to nontrans-
formed WB cells, K anti-peptide antibody detected multiple
bands in cell extracts from transformed GP6 and tumorigenic
GP7TB cells. The size range of these bands is similar to what
has been reported for in vitro translated 512-amino acid LAT-1
(2). Although antibodies from both rabbits reacted with the
recombinant TA1, for reasons that are not known, rabbit serum
FIG. 5. Expression of CD98lc/TA1 and CD98hc/4F2 in cultured
1683 hepatoma cells in response to arginine availability. Total
RNA from 1683 cells cultured in CEM with or without arginine for 24,
48, and 72 h. Northern blot hybridization of total RNA (12 mg) was
analyzed by sequential hybridization to probes for TA1 (top panel),
4F2hc (middle panel), and GAPDH (bottom panel). Ethidium bromide
staining was used as a loading control between lanes. Approximate
transcript sizes are indicated to the right. Both TA1 and 4F2 were
constitutively expressed at high levels in these tumorigenic cells
throughout the time course of the experiment.
FIG. 6. Graphs of relative CD98lc/
TA1 and CD98hc/4F2 mRNA levels in
the various rat hepatic cell lines.
RNA samples from each cell line were
included on the same Northern blot to
yield these comparisons. Each bar repre-
sents the average densitometric value de-
termined from three independent blots. a,
relative units were plotted for TA1 mRNA
levels in the various cell lines cultured in
the presence (open bars) or absence
(closed bars) of arginine for 4, 8, 24, 48, or
72 h. b, relative units were plotted for 4F2
mRNA levels in the various cell lines cul-
tured in the presence (open bars) or ab-
sence (closed bars) of arginine for 72 h.
RNA levels at 72 h are representative of
levels at earlier times because there was
little change in 4F2 RNA levels.
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G reacted only with a band of approximately 35 kDa present in
GP7TB cells. In contrast to the increase observed in message
levels in cells cultured without arginine, no increase was ob-
served in any immunoreactive bands under these culture con-
ditions. None of the bands shown were present after blots were
incubated with the same dilution of nonimmune rabbit serum
(data not shown). Whether the multiple bands detected with
antibody K may correspond to proteolytic fragments or TA1/
LAT-1 cross-reactive molecules is not known.
DISCUSSION
We have examined the response of TA1/CD98lc and 4F2/
CD98hc expression and amino acid transport to arginine avail-
ability in a panel of rat hepatic epithelial cell lines differing in
GGT-expression, transformation, and tumorigenicity. We have
focused our initial studies primarily at the RNA level to assess
changes associated with tumor progression. The CD98 light
chain has been implicated by others in amino acid transport
specificity (2, 6–8, 14). Our results show that steady state
levels of TA1/CD98lc RNA can be up-regulated 10-fold in non-
transformed cells in response to arginine but not glutamine
deprivation, whereas 4F2hc levels only vary by 2-fold under
identical conditions. To our knowledge this is the first demon-
stration that the light and heavy chains of the CD98 complex
respond differentially to an environmental cue. Using this me-
dium formulation, we were not able to deplete other nutrients,
and thus it is not known if the response of CD98lc is specific to
the stress of this amino acid limitation. However, we have not
observed up-regulation after rat hepatic cells are cultured in
conditions of heat shock, hypoxia, or anoxia (data not shown).
This study was not intended to be a complete study of nutrient
response, and further studies are needed to determine the
specificity, threshold, and reversibility of the response.
TA1/CD98lc is constitutively expressed in GGT-positive
transformed WB (both in vitro transformed and tumor-derived)
cells and 1683 cells. When comparing the tumor-derived cell
lines, it is interesting to note that GGT-negative GN6TF cells,
which can modulate TA1 RNA levels in response to amino acid
availability, do not form tumors in the liver, whereas the GGT-
positive tumor-derived cells (GP6TB and GP7TB), which do not
modulate TA1/CD98lc RNA levels, do form tumors rapidly in
the liver (33). 4F2 mRNA levels do not vary significantly in
these cells, although in general the levels are much higher in
transformed versus nontransformed cells (Fig. 6b and compare
4F2 mRNA levels in WB versus GN6, GN6TF, GP6TB, GP7TB,
and 1683). System L activity was also found to respond to
arginine availability and correlated with TA1 mRNA levels in
the cells. Tumorigenic rat hepatic cells express higher basal
and inducible system L activity than nontumorigenic cells. We
have also shown that the loss of response to arginine can occur
at various points in hepatic cell transformation/progression. By
the time the cells have attained tumorigenic capacity, the reg-
ulation is lost.
The correlation between alteration in TA1 regulation and
FIG. 7. Amino acid transport activity of leucine and arginine
in WB and GP7TB cells. The uptake of 100 mM radiolabeled leucine
and arginine was measured in both WB and GP7TB cells cultured in
CEM without arginine (closed bars) or with arginine (open bars) for
48 h. All transport values are expressed as pmol/mg of protein/min.
Each experiment was repeated at least twice with similar results.
Values are the means 6 S.E. of three measurements. Values from a
representative experiment are shown. a, leucine transport was meas-
ured in WB cells. Excess cold tyrosine inhibited leucine transport. b,
arginine transport was measured in WB cells. c, leucine transport was
measured in GP7TB cells. d, arginine transport was measured in
GP7TB cells. Leucine transport was as follows: GP7TB-R . WB-R .
GP7TB 1 R . WB 1 R. These results correlated well with TA1/LAT-1
mRNA levels. Arginine transport did not vary in cells cultured with or
without arginine; however, the tumorigenic GP7TB cell line trans-
ported more arginine than immortalized but not transformed WB cells.
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GGT expression is interesting because hepatic GGT is up-
regulated during carcinogenesis as an early event in neoplastic
conversion (35–37). Hanigan and Ricketts (38) have found that
under conditions of low cysteine, such as those found in the
tumor microenvironment, GGT converts glutathione to a
source of cysteine. Furthermore, GGT expression confers a
selective growth advantage on GGT-positive mouse hepatoma
cells at physiological concentrations of cysteine (34). Similarly,
we hypothesize that TA1 expression may give cells a selective
growth or survival advantage particularly under conditions of
enhanced requirements for amino acids as is found in the
tumor microenvironment (39).
Perhaps not surprisingly, our immunoblot analysis failed to
show an alteration in the total pool of immunoreactive TA1/
LAT-1 comparable with the observed changes in RNA levels or
transport activity, although we did see elevated TA1/LAT-1
protein in transformed and tumorigenic cells relative to non-
transformed cells. These studies are complicated by a number
of factors including assessment of cell surface versus cytoplas-
mic pools of protein, free light chain versus that in complex
with heavy chain and whether antibodies cross-react with
closely related members of the LAT-1 family, including LAT-2,
which may be expressed in these cells. Furthermore, as was
recently demonstrated for the arginine transporter, cat-1,
translation of specific pools of messenger RNAs may be com-
promised under conditions in which amino acids are limiting
(40). Because our light chain anti-peptide antibodies were not
able to immunoprecipitate the CD98 complex, further studies
involving specific heavy chain antibodies and cell localization
or subfractionation will be necessary to fully assess regulation
of this molecule.
Hepatic amino acid transport and transporters are known to
change dramatically during the process of hepatocarcinogen-
esis such that transporters up-regulated in neoplastic cells are
often different from their counterparts in normal cells (41).
There are at least two System L activities in liver: L1 is a high
affinity transporter found in fetal hepatocytes and transformed
cells, and L2 is a low affinity transporter located in freshly
isolated hepatocytes (42, 43). LAT-1/TA1 may correspond to the
L1 transporter, whereas LAT-2 or an unidentified light chain
may correspond to the L2 transporter. The present data do not
exclude the possibility that TA1 is a partial cDNA of LAT-1 or
alternatively that TA1 is a 6-transmembrane variant of the
12-transmembrane form. The detection of an immunoreactive
protein of a smaller size than the 40-kDa major band in GP7TB
cell extracts by two distinct anti-peptide antibodies is notewor-
thy in this regard.
Amino acid availability may be one of the signals that regu-
lates the expression of transport proteins, and loss of response
to amino acid availability may contribute to the neoplastic
process. Some examples of mammalian mRNAs or proteins
whose synthesis is enhanced in response to amino acid depri-
vation include: cat-1 (40), asparagine synthase (44), ornithine
decarboxylase (45, 46), insulin-like growth factor binding pro-
tein-1 (47), System A (48) and System L (49) amino acid trans-
port, and c-jun and c-myc (46, 50). Although modulation of a
System L amino acid transporter by a System y1 substrate may
appear contradictory, there are numerous examples in which
deprivation of amino acids can lead to increases in expression
of genes even though the deprived amino acid is not directly
synthesized/transported by the gene product. Examples in-
clude asparagine synthetase (44), jun, fos, and myc (46), cat-1,
System A, and L17 (50, 51). Kilberg et al. (51) has hypothesized
that mammalian cells may have a general response to amino acid
deprivation similar to the response seen in yeast such that dep-
rivation of any single amino acid up-regulates various activities.
In our current working model, 4F2/CD98hc is proposed to
associate with a low affinity transporter such as LAT-2 or an as
yet unidentified member of the LAT family in the normal adult
hepatocyte. Under conditions of transient nutrient stress, the
high affinity transporter TA1/LAT-1 would be up-regulated
transiently and serve as the major System L activity associated
with 4F2. During hepatic cell transformation/progression to a
tumorigenic cell, this regulation would be lost such that high
affinity System L transport becomes constitutive.
CD98 has been associated with many functions in different
cell types. Up-regulation of TA1 in hepatic cells may conceiv-
ably block or uncouple other (e.g. nontransport) functions in-
cluding CD98 clustering and thereby contribute to neoplastic
transformation. Recently, Hara et al. (52) have shown that
overexpression of human 4F2/CD98hc in murine NIH3T3 cells
resulted in malignant transformation of these cells. Whether
levels of the light chain or heavy to light chain ratios were
affected was not examined in this study. Although it is not yet
known whether 4F2/CD98hc overexpression would have simi-
lar effects in epithelial cells, our studies suggest a potential
mechanism whereby CD98lc may contribute to malignant
transformation of hepatic cells by providing neoplastic cells
with a selective growth advantage, particularly under condi-
tions of nutrient stress. Experiments are underway to test this
hypothesis directly.
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